These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 24089445)

  • 1. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma.
    Sheppard KE; McArthur GA
    Clin Cancer Res; 2013 Oct; 19(19):5320-8. PubMed ID: 24089445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.
    Kong Y; Sheng X; Wu X; Yan J; Ma M; Yu J; Si L; Chi Z; Cui C; Dai J; Li Y; Yu H; Xu T; Tang H; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Guo J
    Clin Cancer Res; 2017 Nov; 23(22):6946-6957. PubMed ID: 28830923
    [No Abstract]   [Full Text] [Related]  

  • 3. Molecular pathways: CDK4 inhibitors for cancer therapy.
    Dickson MA
    Clin Cancer Res; 2014 Jul; 20(13):3379-83. PubMed ID: 24795392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell cycle control as a promising target in melanoma.
    Lee B; Sandhu S; McArthur G
    Curr Opin Oncol; 2015 Mar; 27(2):141-50. PubMed ID: 25588041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
    Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
    Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell Cycle Regulation and Melanoma.
    Xu W; McArthur G
    Curr Oncol Rep; 2016 Jun; 18(6):34. PubMed ID: 27106898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.
    Young RJ; Waldeck K; Martin C; Foo JH; Cameron DP; Kirby L; Do H; Mitchell C; Cullinane C; Liu W; Fox SB; Dutton-Regester K; Hayward NK; Jene N; Dobrovic A; Pearson RB; Christensen JG; Randolph S; McArthur GA; Sheppard KE
    Pigment Cell Melanoma Res; 2014 Jul; 27(4):590-600. PubMed ID: 24495407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin-dependent kinase pathways as targets for women's cancer treatment.
    Konecny GE
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):42-8. PubMed ID: 26642065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment.
    VanArsdale T; Boshoff C; Arndt KT; Abraham RT
    Clin Cancer Res; 2015 Jul; 21(13):2905-10. PubMed ID: 25941111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma.
    Mahgoub T; Eustace AJ; Collins DM; Walsh N; O'Donovan N; Crown J
    Int J Oncol; 2015 Sep; 47(3):900-8. PubMed ID: 26201960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting CDK4/6 in patients with cancer.
    Hamilton E; Infante JR
    Cancer Treat Rev; 2016 Apr; 45():129-38. PubMed ID: 27017286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity.
    Coppock DL; Buffolino P; Kopman C; Nathanson L
    Exp Cell Res; 1995 Nov; 221(1):92-102. PubMed ID: 7589260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cooperation between Cdk4 and p27kip1 in tumor development: a preclinical model to evaluate cell cycle inhibitors with therapeutic activity.
    Sotillo R; Renner O; Dubus P; Ruiz-Cabello J; Martín-Caballero J; Barbacid M; Carnero A; Malumbres M
    Cancer Res; 2005 May; 65(9):3846-52. PubMed ID: 15867383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.
    Teh JL; Purwin TJ; Greenawalt EJ; Chervoneva I; Goldberg A; Davies MA; Aplin AE
    Cancer Res; 2016 Sep; 76(18):5455-66. PubMed ID: 27488531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Getting under the skin: The role of CDK4/6 in melanomas.
    Guo L; Qi J; Wang H; Jiang X; Liu Y
    Eur J Med Chem; 2020 Oct; 204():112531. PubMed ID: 32712436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
    Fåhraeus R; Laín S; Ball KL; Lane DP
    Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting BRAF in melanoma: biological and clinical challenges.
    Mandalà M; Voit C
    Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Several noncontiguous domains of CDK4 are involved in binding to the P16 tumor suppressor protein.
    Ceha HM; Nasser I; Medema RH; Slebos RJ
    Biochem Biophys Res Commun; 1998 Aug; 249(2):550-5. PubMed ID: 9712735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do CDK4/6 inhibitors have potential as targeted therapeutics for squamous cell cancers?
    Kalu NN; Johnson FM
    Expert Opin Investig Drugs; 2017 Feb; 26(2):207-217. PubMed ID: 28042706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin-dependent kinases as therapeutic targets in melanoma.
    Miller DM; Flaherty KT
    Pigment Cell Melanoma Res; 2014 May; 27(3):351-65. PubMed ID: 24405945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.